Partial circumvention of resistance to 6-mercaptopurine by acylated P1,P2-bis(6-mercaptopurine-9-beta-D-ribofuranoside-5') pyrophosphate derivatives.
D000230:Adenocarcinoma; D000818:Animals; D001853:Bone Marrow; D002455:Cell Division / Q000187:drug effects*; D002460:Cell Line; D004305:Dose-Response Relationship, Drug; D004351:Drug Resistance; D006801:Humans; D007939:Leukemia L1210; D015122:Mercaptopurine / Q000494:pharmacology*; D051379:Mice; D013329:Structure-Activity Relationship; D013868:Thioinosine / Q000494:pharmacology; D013873:Thionucleotides / Q000378:metabolism / Q000494:pharmacology*
D013873:Thionucleotides; D013868:Thioinosine; C035479:P(1),P(2)-bis(O(2'),O(3')-dihexanoyl-6-mercaptopurine-9 beta-ribofuranoside)-5'-pyrophosphate; C035478:P(1),P(2)-bis(O(2'),O(3')-dibutyryl-6-mercaptopurine-9 beta-ribofuranoside)-5'-pyrophosphate; C035477:P(1),P(2)-bis(6-mercaptopurine-9 beta-ribofuranoside)-5'-pyrophosphate; D015122:Mercaptopurine